Idera dumps its lead cancer drug program; Pfizer won’t split up after all
Once you work through an explanation of all the reasons Idera Pharmaceuticals $IDRA has found to be optimistic about its ongoing Phase I/II study of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
